Defilade Capital Management L.P. Purchases 303,615 Shares of Henry Schein, Inc. $HSIC

Defilade Capital Management L.P. lifted its position in Henry Schein, Inc. (NASDAQ:HSIC) by 94.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 624,037 shares of the company’s stock after purchasing an additional 303,615 shares during the quarter. Henry Schein makes up 6.5% of Defilade Capital Management L.P.’s investment portfolio, making the stock its 2nd biggest holding. Defilade Capital Management L.P.’s holdings in Henry Schein were worth $45,992,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC acquired a new stake in shares of Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new stake in Henry Schein in the 2nd quarter valued at $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein during the 4th quarter worth $30,000. Federated Hermes Inc. purchased a new position in Henry Schein during the 4th quarter worth $32,000. Finally, Los Angeles Capital Management LLC acquired a new position in Henry Schein in the fourth quarter valued at $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In other news, Director William K. Daniel bought 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.89% of the company’s stock.

Henry Schein Price Performance

HSIC stock opened at $85.75 on Monday. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average price is $82.19 and its 200 day moving average price is $78.30. Henry Schein, Inc. has a 52 week low of $61.94 and a 52 week high of $89.34. The company has a market cap of $9.77 billion, a P/E ratio of 25.91, a P/E/G ratio of 1.65 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period last year, the company posted $1.15 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HSIC has been the subject of several recent research reports. Morgan Stanley reiterated an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. BTIG Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, June 11th. Mizuho cut their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. BMO Capital Markets assumed coverage on Henry Schein in a report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price target for the company. Finally, UBS Group reissued a “neutral” rating and issued a $89.00 price objective (up from $85.00) on shares of Henry Schein in a research note on Tuesday, July 28th. Eight research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $89.36.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.